Pembro Plus Chemo Now for First-Line Metastatic Squamous NSCLC Pembro Plus Chemo Now for First-Line Metastatic Squamous NSCLC

The FDA has granted approval for immunotherapy with pembrolizumab in combination with chemotherapy to be used first-line in metastatic squamous nonsmall cell lung cancer.FDA Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news